Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.

doi:10.1158/1078-0432.CCR-22-0931

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.

Clinical cancer research : an official journal of the American Association for Cancer Research - 4 Jan 2023

Chi Kim N, Barnicle Alan, Sibilla Caroline, Lai Zhongwu, Corcoran Claire, Barrett J Carl, Adelman Carrie A, Qiu Ping, Easter Ashley, Dearden Simon, Oxnard Geoffrey R, Agarwal Neeraj, Azad Arun, de Bono Johann, Mateo Joaquin, Olmos David, Thiery-Vuillemin Antoine, Harrington Elizabeth A

Abstract excerpt

PURPOSE: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimization of screening techniques may reduce failure rates; however, a need remains for additional testing methods to detect cancers with alterations in homologous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxia Telangiectasia Mutated Proteins

Share to Biomarkers, Tumor

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Circulating Tumor DNA

Share to Clinical Trials, Phase III as Topic

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 36043882
DOI: 10.1158/1078-0432.CCR-22-0931
PMCID: PMC9811161

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.PMID 36043882Read ↗

Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.Semantic proximity Read ↗

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.Semantic proximity Read ↗

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 , or ATM Alterations Identified by Testing Circulating Tumor DNASemantic proximity Read ↗

Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in GermanySemantic proximity Read ↗

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.Semantic proximity Read ↗

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testingSemantic proximity Read ↗

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.Semantic proximity Read ↗

Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNASemantic proximity Read ↗

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.Semantic proximity Read ↗

Practical Utility of Liquid Biopsies for Evaluating Genomic Alterations in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.